Taiwan · Delayed Price · Currency is TWD RBC Bioscience Statistics
Total Valuation
RBC Bioscience has a market cap or net worth of TWD 281.19 million. The enterprise value is 635.92 million.
| Market Cap | 281.19M |
| Enterprise Value | 635.92M |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | Oct 2, 2025 |
Share Statistics
RBC Bioscience has 14.27 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 14.27M |
| Shares Outstanding | 14.27M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 29.42% |
| Owned by Institutions (%) | n/a |
| Float | 8.02M |
Valuation Ratios
The trailing PE ratio is 12.01.
| PE Ratio | 12.01 |
| Forward PE | n/a |
| PS Ratio | 1.28 |
| PB Ratio | 1.05 |
| P/TBV Ratio | 1.12 |
| P/FCF Ratio | 8.25 |
| P/OCF Ratio | 6.94 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.59, with an EV/FCF ratio of 18.66.
| EV / Earnings | 27.01 |
| EV / Sales | 2.89 |
| EV / EBITDA | 12.59 |
| EV / EBIT | 18.16 |
| EV / FCF | 18.66 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 1.46.
| Current Ratio | 1.25 |
| Quick Ratio | 0.66 |
| Debt / Equity | 1.46 |
| Debt / EBITDA | 7.75 |
| Debt / FCF | 11.48 |
| Interest Coverage | 3.61 |
Financial Efficiency
Return on equity (ROE) is 9.09% and return on invested capital (ROIC) is 4.44%.
| Return on Equity (ROE) | 9.09% |
| Return on Assets (ROA) | 2.94% |
| Return on Invested Capital (ROIC) | 4.44% |
| Return on Capital Employed (ROCE) | 5.57% |
| Weighted Average Cost of Capital (WACC) | 3.87% |
| Revenue Per Employee | 4.39M |
| Profits Per Employee | 470,860 |
| Employee Count | 50 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 2.36 |
Taxes
In the past 12 months, RBC Bioscience has paid 6.25 million in taxes.
| Income Tax | 6.25M |
| Effective Tax Rate | 20.99% |
Stock Price Statistics
The stock price has increased by +20.53% in the last 52 weeks. The beta is 0.42, so RBC Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +20.53% |
| 50-Day Moving Average | 18.94 |
| 200-Day Moving Average | 17.57 |
| Relative Strength Index (RSI) | 68.98 |
| Average Volume (20 Days) | 28,035 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RBC Bioscience had revenue of TWD 219.71 million and earned 23.54 million in profits. Earnings per share was 1.64.
| Revenue | 219.71M |
| Gross Profit | 101.46M |
| Operating Income | 35.03M |
| Pretax Income | 29.80M |
| Net Income | 23.54M |
| EBITDA | 49.27M |
| EBIT | 35.03M |
| Earnings Per Share (EPS) | 1.64 |
Balance Sheet
The company has 36.44 million in cash and 391.17 million in debt, with a net cash position of -354.73 million or -24.85 per share.
| Cash & Cash Equivalents | 36.44M |
| Total Debt | 391.17M |
| Net Cash | -354.73M |
| Net Cash Per Share | -24.85 |
| Equity (Book Value) | 268.54M |
| Book Value Per Share | 18.81 |
| Working Capital | 24.06M |
Cash Flow
In the last 12 months, operating cash flow was 40.52 million and capital expenditures -6.44 million, giving a free cash flow of 34.08 million.
| Operating Cash Flow | 40.52M |
| Capital Expenditures | -6.44M |
| Depreciation & Amortization | 14.25M |
| Net Borrowing | -64.23M |
| Free Cash Flow | 34.08M |
| FCF Per Share | 2.39 |
Margins
Gross margin is 46.18%, with operating and profit margins of 15.94% and 10.72%.
| Gross Margin | 46.18% |
| Operating Margin | 15.94% |
| Pretax Margin | 13.56% |
| Profit Margin | 10.72% |
| EBITDA Margin | 22.43% |
| EBIT Margin | 15.94% |
| FCF Margin | 15.51% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 7.61%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 7.61% |
| Dividend Growth (YoY) | -67.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.19% |
| Buyback Yield | -0.18% |
| Shareholder Yield | 7.47% |
| Earnings Yield | 8.37% |
| FCF Yield | 12.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 11, 2025. It was a forward split with a ratio of 1.1.
| Last Split Date | Aug 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
RBC Bioscience has an Altman Z-Score of 0.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.98 |
| Piotroski F-Score | 6 |